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Introduction 
Outcomes for patients in the UK with LA NSCLC are amongst the lowest in Europe with 5-year 
survival of around 10%  compared to up to 20% in other countries 1,2.  
  
Progression free survival (PFS) and overall survival (OS) are key outcome measures for lung cancer. 
Assessing these outcomes is important for analysing the effectiveness of current trends in practice.  
 
Aim 
This project will investigate the use of routine healthcare datasets to determine PFS and OS of 
patients treated with radical radiotherapy for LA NSCLC. 
 
 
Method 
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Motivations 
• “A Vision for Radiotherapy 2014- 2024”- national strategy to evaluate radiotherapy 
services  
• Radiotherapy plays an important role in the treatment of patients with LA NSCLC so 
developing an algorithm that rapidly analyses outcomes of these patients is valuable for 
research and strategic planning of service provision. 
Challenges to assessing outcomes 
• Currently reliant on the quality, completeness and consistency of data from hospital 
records (manual data) 
• Manual data 
- Advantages: most accurately identifies clinically significant events; considered the Gold 
Standard 
- Disadvantages: data quality can be inconsistent; collecting and analysing data is labour-
intensive 
• Routine data 
- Advantages: Nationally collected data is an alternative source for data analyses 
- Disadvantages: Does not include a diagnosis or recurrence date so proxy time points are 
used to extract this data from the routine dataset 
Graph 1. Correlation between manual and routine derived PFS intervals determined by algorithm. Pearson correlation 
coefficient of 0.916. ¥ Patient diagnosed and chemotherapy initiated in peripheral hospital resulting in routine diagnosis date being 
later with a subsequently shorter PFS interval. Ϯ Unconventional use of systemic treatment resulting in algorithm incorrectly 
identifying a recurrence event.  § Algorithm identifies a later date as the recurrence date from routine data resulting in longer PFS 
interval. 
Graph 2. Correlation between manual and routine derived OS  intervals determined by algorithm. Pearson correlation coefficient 
of 0.990. ¥ Patient diagnosed and chemotherapy initiated in a peripheral hospital resulting in routine diagnosis date being later 
with a subsequently shorter OS interval. 
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Figure 2. Diagram showing  the clinical events defining PFS and OS from manual data and the identifiable proxy events used as a surrogate 
from routine datasets.3 
Results 
• 20 patients identified for the pilot study 
• Manual data:  median PFS=19.68m;  median OS= 23.61m 
• Routine data:  median PFS= 19.18m;  median OS=23.83m 
• 15/20 and 11/20 routine diagnosis dates are within 4 weeks and 2 weeks of manual 
diagnosis dates, respectively; 5/20 diagnosis dates match exactly. 
• 2 patients have >60day difference in routine and manual diagnosis dates: 1 patient had 
repeated negative biopsies prior to a positive diagnosis; 1 patient was referred from a 
peripheral hospital where diagnosis and  chemotherapy had been initiated. 
• 8 recurrences detected by algorithm. 2/8 recurrences not detected by algorithm as those 
patients did not receive secondary treatment. 1 incorrect recurrence event detected by 
algorithm due to unconventional use of systemic treatment. 
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Figure 1. Flow chart showing the process of manual and routine data analysis for patients with LA NSCLC. Relevant time points are  
identified (¥ refer to figure 2) and used to calculate PFS and OS intervals for the data sets which are then compared to assess agreement. 
An algorithm is then developed to  automate this process  using backdating and time interval optimisation to refine the process.  
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Figure 3. Flow chart showing the algorithm process of merging the various routine datasets to identify dates of diagnosis, recurrence and 
death or last follow-up appointment and then calculation of PFS and OS. 
¥ 
Ϯ 
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Limitations 
• Quality of routine data eg. missing ICD10 codes means that the earliest lung cancer ICD10 
identified by algorithm is not actually the first known instance; missing OPCS codes means 
algorithm cannot backdate to a diagnostic event.  
• Routine data is incomplete for patients referred from other hospitals. 
• Recurrence is not reliably detected if no secondary treatment is delivered. 
Conclusions 
• This is a novel approach to use routine datasets to determine outcome indicators in 
patients with LA NSCLC that will be a surrogate to analysing manual data.  
• An algorithm has been developed to enable automated interpretation of routine datasets 
for patients with LA NSCLC and is being refined to improve data correlation. 
• This method can be adjusted to auto-analyse outcomes for other stages of NSCLC. 
• The ability to enable efficient and large scale analysis of current lung cancer strategies has 
a huge potential impact on the healthcare system. 
